Darnell A. Pouncil

Array ( [id] => 18910362 [patent_doc_number] => 11873332 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Lyophilized formulation of a monoclonal antibody against transthyretin [patent_app_type] => utility [patent_app_number] => 16/767994 [patent_app_country] => US [patent_app_date] => 2018-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22212 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16767994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649493 [patent_doc_number] => 20190231875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/198171 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16198171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020561 [patent_doc_number] => 20190321285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => FORMULATIONS OF ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/197228 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16197228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19666154 [patent_doc_number] => 12178874 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof [patent_app_type] => utility [patent_app_number] => 16/763193 [patent_app_country] => US [patent_app_date] => 2018-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 18405 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16763193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18869845 [patent_doc_number] => 11857625 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Pharmaceutical compositions [patent_app_type] => utility [patent_app_number] => 16/765786 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18748 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16765786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511448 [patent_doc_number] => 20200390705 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => METHOD FOR REDUCING THE RECONSTITUTION TIME OF SPRAY-DRIED PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/764338 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16764338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19593172 [patent_doc_number] => 12150990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody [patent_app_type] => utility [patent_app_number] => 16/756409 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11515 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16756409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016599 [patent_doc_number] => 20190070293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/178309 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16178309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016601 [patent_doc_number] => 20190070294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/178319 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16178319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16197442 [patent_doc_number] => 10722579 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Stable aqueous formulations of adalimumab [patent_app_type] => utility [patent_app_number] => 16/178137 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 35703 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16178137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016597 [patent_doc_number] => 20190070292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/178164 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16178164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15765621 [patent_doc_number] => 20200113828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => Thermally Stabilized Nanoemulsion [patent_app_type] => utility [patent_app_number] => 16/350199 [patent_app_country] => US [patent_app_date] => 2018-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16350199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306465 [patent_doc_number] => 20190142936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => DRY SOLID ALUMINUM ADJUVANT-CONTAINING VACCINES AND RELATED METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/156511 [patent_app_country] => US [patent_app_date] => 2018-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16156511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14130199 [patent_doc_number] => 20190099489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => Novel Formulations Which Stabilize Low Dose Antibody Compositions [patent_app_type] => utility [patent_app_number] => 16/145324 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16145324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16998402 [patent_doc_number] => 11077184 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response [patent_app_type] => utility [patent_app_number] => 16/139361 [patent_app_country] => US [patent_app_date] => 2018-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 21233 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16139361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688374 [patent_doc_number] => 20210070850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => PHARMACEUTICAL FORMULATIONS FOR ADALIMUMAB [patent_app_type] => utility [patent_app_number] => 16/646864 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14019005 [patent_doc_number] => 20190071496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => PHARMACEUTICAL FORMULATIONS OF TNF-ALPHA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/123293 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6658 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16123293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243516 [patent_doc_number] => 20210363259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS CONTAINING ANTI-ALPHA(V)BETA(6) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/640422 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806188 [patent_doc_number] => 20210128741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ANTIBODY-DRUG CONJUGATE PREPARATION AND LYOPHILIZATION FOR SAME [patent_app_type] => utility [patent_app_number] => 16/640914 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21903 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915862 [patent_doc_number] => 20210188954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA AMYLOID ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/639338 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15469 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639338 [rel_patent_id] =>[rel_patent_doc_number] =>)